Entries by CAPTIS

Old video surfaces showing Mayo Clinic CEO prioritizing patients with private insurance

Left to right, Mayo Clinic CEO John Noseworthy, VA Under Secretary for Health Dr. David J. Shulkin and former VA Secretary James B. Peake discuss telemedicine at ATA 2016. Looks like Paul Ryan isn’t the only one being embarrassed by the surfacing of old videos. Mayo Clinic CEO Dr. John Noseworthy is under fire after […]

Four Former FDA Commissioners Warn About Drug Importation Dangers

Last week, four former FDA Commissioners – Robert M. Califf, Margaret B. Hamburg, Mark B. McClellan, and Andrew Von Eschenbach – wrote an open letter to members of Congress warning them about the risk of legalizing importation of drugs. The Washington Post outlines how these former FDA heads – who served in both Democrat and […]

BMS signs new $200M licensing deal for CytomX probodies

Bristol-Myers Squibb (BMS) is back for seconds, dropping $200 million for up to eight more “probody” drug candidates from CytomX Therapeutics. Announced Monday, the deal also outlines a potential boost of “up to $448 million in future development, regulatory and sales milestone payments for each collaboration target.” In a perfect (probably unrealistic world) that would amount […]

Lawmakers wrestle with the promise and risk of drug importation

On December 8, 2003, President George W. Bush signed into law the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“MMA”). The MMA sought to ensure access to medically necessary prescription drugs. This involved mandating the passage of regulations to allow importation of prescription drugs from Canada into the U.S. upon certification of the […]

eGenesis bets on CRISPR to domesticate pig organs for safer xenotransplantation

Boston-based eGenesis recently received $38 million in Series A financing to develop a safer xenotransplant. Founded by research superstar and serial entrepreneur George Church and former Church lab scientist Luhan Yang, the company is using CRISPR gene editing to make pig organs suitable for human transplantation. The need is great. Around 120,000 people are on […]

Pharma TV ad spend promoting prescription drugs has increased 62 percent since 2012

Laura Ries was moved to action when she saw a TV commercial that portrayed a woman enjoying time with her grandchildren after taking Lyrica, a prescription medication for diabetic nerve pain. Ries’ elderly mother suffered from just that problem. “The ad showed someone who was enjoying life again,” said Ries, president of a marketing strategy […]

Can a 3D printing network for VA hospitals realize ambitions for customized prosthetics?

Photo: Stratasys’ 3D technology Stratasys has established a 3D printing lab network as part of an agreement with Center for Innovation at the Department of Veterans Affairs. The move signals the medtech company’s ambitions to move customized prosthetics into the mainstream of healthcare. The agreement with the Center for Innovation at the Department of Veterans Affairs will […]

Oxford BioDynamics participates in rheumatoid arthritis triggers study

Published 20 March 2017 Oxford BioDynamics is participating in a collaboration to identify the biological factors that trigger disease relapses, known as flares, in Rheumatoid Arthritis (RA), entitled the BIO-FLARE study (Biological factors that limit sustained remission in Rheumatoid Arthritis). Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory […]

Circassia signs deal for US rights to two AstraZeneca COPD drugs

PBR Staff Writer Published 20 March 2017 UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD). Circassia has agreed to pay AstraZeneca $50m worth of its ordinary shares under the deal, which is expected […]

Novartis’ heart failure drug Entresto improves glycemic control in Phase III study

Published 20 March 2017 Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril. HFrEF is also known as systolic heart failure (HF). […]